# Cuproptosis-related gene signatures define immune subtypes and predict prognosis in gastric cancer

**Authors:** Zhe Wang, Yuxin Man, Bingtong Yue, Min Liu, Jiayi Zhang, Feng Wang, Dao Xin

PMC · DOI: 10.3389/fmolb.2026.1746613 · Frontiers in Molecular Biosciences · 2026-02-09

## TL;DR

This study explores how cuproptosis-related genes influence immune subtypes and survival in gastric cancer, offering new insights for immunotherapy.

## Contribution

The study identifies a novel five-gene signature linked to cuproptosis and immune features in gastric cancer.

## Key findings

- Three cuproptosis-related molecular subtypes were identified in gastric adenocarcinoma.
- A five-gene signature (PEG10, RPL39L, MMP11, SYNPO2, KRT17) correlates with survival and immune markers.
- The gene signature is associated with immune heterogeneity and potential immunotherapy implications.

## Abstract

Despite recent improvements in diagnostic and therapeutic strategies, gastric cancer (GC) continues to be a major contributor to global cancer fatalities, resulting in suboptimal patient prognosis overall. Cuproptosis, defined as a regulated death mode initiated by intracellular copper overload, has not been comprehensively examined in the context of the tumor immune microenvironment or its prognostic relevance in stomach adenocarcinoma.

Comprehensive transcriptomic analyses of TCGA and GEO cohorts were performed to identify cuproptosis-related molecular subtypes and to develop a prognostic risk model based on cuproptosis-associated genes. Correlations between the risk score and features of the TIME were thoroughly evaluated. RT-qPCR was conducted in 14 paired gastric tumor and adjacent normal tissues to validate the expression of key prognostic genes.

Three distinct cuproptosis-associated molecular subtypes were identified in STAD. A five-gene prognostic signature—PEG10, RPL39L, MMP11, SYNPO2, and KRT17—was established, which showed strong associations with overall survival and multiple immunological indicators, including immune cell infiltration, MSI, TMB, immune checkpoint expression, and HLA profiles. Subsequently, a nomogram provided enhanced individualized survival prediction.

The identified cuproptosis-related gene signature is associated with the immunological heterogeneity of gastric cancer. Together, these results point to previously unrecognized links between cuproptosis and antitumor immunity, may provide insights for refining immunotherapeutic strategies in gastric cancer. Continued experimental investigation will be necessary to unravel how cuproptosis contributes to gastric cancer development and to validate its association with immune regulation.

## Linked entities

- **Genes:** PEG10 (paternally expressed 10) [NCBI Gene 23089], RPL39L (ribosomal protein L39 like) [NCBI Gene 116832], MMP11 (matrix metallopeptidase 11) [NCBI Gene 4320], SYNPO2 (synaptopodin 2) [NCBI Gene 171024], KRT17 (keratin 17) [NCBI Gene 3872]
- **Diseases:** gastric cancer (MONDO:0001056), gastric adenocarcinoma (MONDO:0005036)

## Full-text entities

- **Genes:** MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, Slc31a1 (solute carrier family 31, member 1) [NCBI Gene 20529] {aka 4930445G01Rik, Ctr1}, CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 1493] {aka ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, TTN (titin) [NCBI Gene 7273] {aka CMD1G, CMH9, CMPD4, CMYO5, CMYP5, EOMFC}, Cd274 (CD274 antigen) [NCBI Gene 60533] {aka A530045L16Rik, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1}, DLAT (dihydrolipoamide S-acetyltransferase) [NCBI Gene 1737] {aka DLTA, E2, PBC, PDC-E2, PDCE2}, DLD (dihydrolipoamide dehydrogenase) [NCBI Gene 1738] {aka DLDD, DLDH, E3, GCSL, LAD, OGDC-E3}, PDHB (pyruvate dehydrogenase E1 subunit beta) [NCBI Gene 5162] {aka E1beta, PDHBD, PDHE1-B, PDHE1B, PHE1B}, HLA-DMA (major histocompatibility complex, class II, DM alpha) [NCBI Gene 3108] {aka D6S222E, DMA, HLADM, RING6}, RPL17 (ribosomal protein L17) [NCBI Gene 6139] {aka DBA22, L17, PD-1, RPL23, uL22}, RPS6KB1 (ribosomal protein S6 kinase B1) [NCBI Gene 6198] {aka PS6K, S6K, S6K-beta-1, S6K1, STK14A, p70 S6KA}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, CD160 (CD160 molecule) [NCBI Gene 11126] {aka BY55, NK1, NK28}, KIR3DL1 (killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1) [NCBI Gene 3811] {aka CD158E1, KIR, KIR3DL1/S1, NKAT-3, NKAT3, NKB1}, ICOS (inducible T cell costimulator) [NCBI Gene 29851] {aka AILIM, CD278, CVID1}, JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, PDHA1 (pyruvate dehydrogenase E1 subunit alpha 1) [NCBI Gene 5160] {aka E1alpha, PDHA, PDHAD, PDHCE1A, PHE1A}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, HLA-A (major histocompatibility complex, class I, A) [NCBI Gene 3105] {aka HLAA}, MMP11 (matrix metallopeptidase 11) [NCBI Gene 4320] {aka SL-3, ST3, STMY3}, KRT17 (keratin 17) [NCBI Gene 3872] {aka 39.1, CK-17, K17, PC2, PCHC1}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, LIAS (lipoic acid synthetase) [NCBI Gene 11019] {aka HGCLAS, HUSSY-01, LAS, LIP1, LS, PDHLD}, MTF1 (metal regulatory transcription factor 1) [NCBI Gene 4520] {aka MTF-1, ZRF}, RPL39 (ribosomal protein L39) [NCBI Gene 6170] {aka L39, RPL39P42, RPL39_23_1806, eL39}, CD276 (CD276 molecule) [NCBI Gene 80381] {aka 4Ig-B7-H3, B7-H3, B7H3, B7RP-2}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, LIPT1 (lipoyltransferase 1) [NCBI Gene 51601] {aka LIPT1D}, MAP2K1 (mitogen-activated protein kinase kinase 1) [NCBI Gene 5604] {aka CFC3, MAPKK1, MEK1, MEL, MKK1, PRKMK1}, SYNPO2 (synaptopodin 2) [NCBI Gene 171024], STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, NRP1 (neuropilin 1) [NCBI Gene 8829] {aka BDCA4, CD304, NP1, NRP, VEGF165R}, RPL39L (ribosomal protein L39 like) [NCBI Gene 116832] {aka L39-2, RPL39L1}, ULK1 (unc-51 like autophagy activating kinase 1) [NCBI Gene 8408] {aka ATG1, ATG1A, UNC51, Unc51.1, hATG1}, HLA-F (major histocompatibility complex, class I, F) [NCBI Gene 3134] {aka CDA12, HLA-5.4, HLA-CDA12, HLAF}, TNFSF4 (TNF superfamily member 4) [NCBI Gene 7292] {aka CD134L, CD252, GP34, OX-40L, OX4OL, TNLG2B}, LGALS9 (galectin 9) [NCBI Gene 3965] {aka HUAT, LGALS9A}, PEG10 (paternally expressed 10) [NCBI Gene 23089] {aka EDR, HB-1, MEF3L, Mar2, Mart2, RGAG3}, CHD7 (chromodomain helicase DNA binding protein 7) [NCBI Gene 55636] {aka CRG, HH5, IS3, KAL5}, ULK2 (unc-51 like autophagy activating kinase 2) [NCBI Gene 9706] {aka ATG1B, Unc51.2}, LRP1B (LDL receptor related protein 1B) [NCBI Gene 53353] {aka LRP-1B, LRP-DIT, LRPDIT}, PDE3B (phosphodiesterase 3B) [NCBI Gene 5140] {aka HcGIP1, cGIPDE1}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, FDX1 (ferredoxin 1) [NCBI Gene 2230] {aka ADX, FDX, LOH11CR1D}, Egfr (epidermal growth factor receptor) [NCBI Gene 13649] {aka 9030024J15Rik, Erbb, Errb1, Errp, Wa5, wa-2}, MAP2K2 (mitogen-activated protein kinase kinase 2) [NCBI Gene 5605] {aka CFC4, MAPKK2, MEK2, MKK2, PRKMK2}
- **Diseases:** metastasis (MESH:D009362), toxicity (MESH:D064420), HPA (MESH:C483996), CNV (OMIM:610141), gastrointestinal tumors (MESH:D005770), Tumor Node Metastasis (MESH:D008207), bladder cancer (MESH:D001749), Tumor-Associated Macrophage (MESH:D000072716), H (MESH:D000848), inflammatory (MESH:D007249), MSI (MESH:D053842), Cancer (MESH:D009369), Gastric Cancer (MESH:D013274), TAM (MESH:D020914), MSS disease (MESH:D013132), oral squamous cell carcinoma (MESH:D000077195), OS (MESH:C567932)
- **Chemicals:** ROS (-), pazopanib (MESH:C516667), TCA (MESH:D014238), steroid (MESH:D013256), docetaxel (MESH:D000077143), metal (MESH:D008670), Tricarboxylic Acid (MESH:D014233), imatinib (MESH:D000068877), lapatinib (MESH:D000077341), Copper (MESH:D003300), sorafenib (MESH:D000077157)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12926107/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12926107/full.md

## References

38 references — full list in the complete paper: https://tomesphere.com/paper/PMC12926107/full.md

---
Source: https://tomesphere.com/paper/PMC12926107